Disclosed is the use of bevacizumab in the preparation of a medicament for improving the progression-free survival of a patient suffering from metastatic colorectal cancer, wherein the medicament is for administration to the patient in combination with a chemotherapy regimen, and wherein the patient has been determined to have an increased level of VEGFA relative to control levels determined in patients diagnosed with metastatic colorectal cancer.
